[go: up one dir, main page]

PE20230838A1 - Derivados de sulfona - Google Patents

Derivados de sulfona

Info

Publication number
PE20230838A1
PE20230838A1 PE2022002959A PE2022002959A PE20230838A1 PE 20230838 A1 PE20230838 A1 PE 20230838A1 PE 2022002959 A PE2022002959 A PE 2022002959A PE 2022002959 A PE2022002959 A PE 2022002959A PE 20230838 A1 PE20230838 A1 PE 20230838A1
Authority
PE
Peru
Prior art keywords
alkyl
alkoxy
halo
halogen
1hpyrazolo
Prior art date
Application number
PE2022002959A
Other languages
English (en)
Inventor
Andrew Simon Bell
Jeremy Besnard
Anthony Richard Bradley
Luke Green
Wolfgang Haap
Buelent Kocer
Andreas Kuglstatter
Xavier Lucas
Patrizio Mattei
Dmitry Mazunin
Claus Riemer
Hoorn Willem Paul Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20230838A1 publication Critical patent/PE20230838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona compuestos de formula I; en donde X1 es N o C; X2 es N o CR4; X3 es N o CR5; X4 es N o CH; siempre que no mas de dos de X1, X2 y X3 representan N; las lineas punteadas representan un enlace simple o doble; R1 es -SO2R1a o -SOR1b; cada R2', R2", R3' y R3" es independientemente, H, halogeno, -NH2, alquilo (C1-C6), alcoxi (C1-C6), halo-alquilo (C1- C6) o halo-alcoxi (C1-C6); R6 es halogeno, alquilo (C1-C6), alcoxi (C1-C6), ciano, halo-alquilo (C1-C6), entre otros; R7 es H, halogeno, hidroxi, alquilo (C1-C6), alcoxi (C1-C6), entre otros. Un compuesto seleccionado es 3-ciclopropil-4-(3-metil-4-(metilsulfonil) fenil)-1Hpirazolo[4,3-c]piridina, 3-ciclopropil-4-(3-metil-4-(metilsulfonil) fenil)-1Hpirazolo[4,3-c]piridina. Dichoa compuestos son son inhibidores de la metionina adenosiltransferasa 2A (Mat2A) de humano. Tambien se refiere a una composicion farmaceutica que lo comprende; siendo util en en el tratamiento, prevencion y/o retraso de la progresion del cancer.
PE2022002959A 2020-06-22 2021-06-21 Derivados de sulfona PE20230838A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181363 2020-06-22
PCT/EP2021/066767 WO2021259831A1 (en) 2020-06-22 2021-06-21 Sulfone derivatives

Publications (1)

Publication Number Publication Date
PE20230838A1 true PE20230838A1 (es) 2023-05-19

Family

ID=71120071

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002959A PE20230838A1 (es) 2020-06-22 2021-06-21 Derivados de sulfona

Country Status (18)

Country Link
US (1) US20230219953A1 (es)
EP (1) EP4168392A1 (es)
JP (1) JP7731381B2 (es)
KR (1) KR20230026479A (es)
CN (1) CN115916756A (es)
AR (1) AR122705A1 (es)
AU (1) AU2021294933A1 (es)
BR (1) BR112022026105A2 (es)
CA (1) CA3187145A1 (es)
CL (1) CL2022003677A1 (es)
CO (1) CO2023000117A2 (es)
CR (1) CR20220644A (es)
IL (1) IL298824A (es)
MX (1) MX2022016455A (es)
PE (1) PE20230838A1 (es)
TW (1) TWI812966B (es)
WO (1) WO2021259831A1 (es)
ZA (1) ZA202213430B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
EP2408772B1 (en) 2009-03-19 2015-07-01 Medical Research Council Technology Compounds
CA2782727C (en) 2009-12-04 2017-03-14 Taisho Pharmaceutical Co., Ltd. 2-pyridone compounds
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
WO2012138678A1 (en) 2011-04-04 2012-10-11 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
JP2014525451A (ja) 2011-08-29 2014-09-29 ピーティーシー セラピューティクス， インコーポレイテッド 抗菌化合物および使用方法
WO2013130855A1 (en) * 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
CN104837839A (zh) 2012-11-08 2015-08-12 辉瑞公司 作为多巴胺d1配体的杂芳族化合物
EP3036230A1 (en) 2013-08-22 2016-06-29 F. Hoffmann-La Roche AG Alkynyl alcohols and methods of use
CA2965741C (en) * 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP3894396A1 (en) * 2018-12-10 2021-10-20 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
MA54609A (fr) * 2018-12-27 2022-04-06 Les Laboratoires Servier Sas Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
KR20230026479A (ko) 2023-02-24
CR20220644A (es) 2023-02-17
EP4168392A1 (en) 2023-04-26
ZA202213430B (en) 2023-08-30
TW202208361A (zh) 2022-03-01
JP2023531020A (ja) 2023-07-20
IL298824A (en) 2023-02-01
BR112022026105A2 (pt) 2023-01-17
CO2023000117A2 (es) 2023-04-27
MX2022016455A (es) 2023-02-01
US20230219953A1 (en) 2023-07-13
AU2021294933A1 (en) 2023-02-02
CL2022003677A1 (es) 2023-07-28
AR122705A1 (es) 2022-09-28
CN115916756A (zh) 2023-04-04
CA3187145A1 (en) 2021-12-30
JP7731381B2 (ja) 2025-08-29
TWI812966B (zh) 2023-08-21
WO2021259831A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
JOP20200288A1 (ar) مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
MX2021006841A (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
TNSN07022A1 (fr) Derives de pyridine
MA27467A1 (fr) Quinolones anti-microbiens, leurs compositions et utilisations
BR0113448A (pt) Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase
BR112022014480A2 (pt) Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
PE20030447A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol-3-il)-sustituidos y su obtencion
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
NO20070580L (no) Behandling av cancer.
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
PE20230838A1 (es) Derivados de sulfona
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
ECSP055781A (es) Composiciones oftálmicas para el tratamiento de la hipertensión ocular
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2025010920A (es) Compuestos quimicos
PE20190151A1 (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3